Bolt Biotherapeutics is a biotechnology company focused on immuno-oncology agents for eliminating tumor cells by the immune system. They have three programs in development, including BDC-1001 for HER2-expressing solid tumors, BDC-2034 for various cancer types, and BDC-3042 for targeting cell-surface receptors on macrophages. The company is also working on a program for nonresponsive tumors.